eisai china lnc.-威尼斯人888

about eisai china
about us

eisai’s affiliates in china are wholly-owned by eisai co., ltd. (eisai), a japanese multinational pharmaceutical company with strong r&d capabilities, as global headquarter in tokyo and headquarter of china in shanghai.

eisai has grown smoothly since entering the chinese market in the early 1990s and the total …

more
威尼斯人888
contact us seek cooperation
chinese news
the news
31
2021/03
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, "eisai") and msd k.k. (headquarters: tokyo, president: kyle tattle, "msd"), a subsidiary of merck & co., inc., kenilworth, n.j., u.s.a., (known as msd outside the united states and canada) announced today that eisai has submitted an application in japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, lenvima® (generic name: lenvatinib mesylate), in combination with merck & co., inc., kenilworth, n.j., u.s.a.’s keytruda® (generic name: pembrolizumab) as a treatment for patients with advanced renal cell carcinoma (rcc). this is the first application to be submitted in japan for this combination therapy.
31
2021/03
kyorin pharmaceutical co., ltd. (headquarters: chiyoda-ku, tokyo, president and ceo: shigeru ogihara, "kyorin"), a subsidiary of kyorin holdings, inc. (headquarters: chiyoda-ku, tokyo, president and ceo: yutaka ogihara), and eisai co., ltd. (headquarters: bunkyo-ku, tokyo, ceo: haruo naito, "eisai") have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four asean (association of southeast asian nations) member states; thailand, the philippines, malaysia and brunei. based on this agreement, eisai will acquire exclusive development and marketing rights from kyorin for the agent in the said four countries, and will be responsible for submitting a new drug application for the agent.
30
2021/03
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the european medicines agency (ema) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate (product name: lenvima® / kisplyx®, “lenvatinib”), in combination with anti-pd-1 therapy pembrolizumab (brand name: keytruda®), developed by merck & co., inc., kenilworth, n.j., u.s.a., (known as msd outside the united states and canada) as a treatment f or patients with advanced renal cell carcinoma (rcc) and advanced endometrial carcinoma (ec), respectively.
10
2020/12
if approved, aducanumab would become the first treatment to meaningfully change the course of alzheimer’s disease aducanumab is now under regulatory review in japan, europe and the united states
30
2020/11
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, "eisai") announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (aed) perampanel (product name: fycompa®), at the 74th american epilepsy society annual meeting (aes2020), to be held virtually from december 4 to 8, 2020.
30
2020/11
this collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of α-synuclein misfolding and aggregation
more

1066vip威尼斯 copyright(c) 2011 eisai china lnc.all rights reserved.

沪公网安备31010602001439号

customer service hotline

021-62881220

links



• 已上市替普瑞酮胶囊铬限量检验报告公示说明

more information

• privacy policy
• legal notices
• accessibility

网站地图